Purpose: The aim of the study was to evaluate whether or not MRCP using a 3D-SPACE sequence allows for better image quality and a higher level of diagnostic confidence than a conventional 3D-TSE sequence at 1.5 T regarding the diagnosis of choledocholithiasis in a routine clinical setting.
Materials And Methods: 3D-SPACE and 3D-TSE sequences were performed in 42 consecutive patients with suspected choledocholithiasis undergoing MRCP. Evaluation of image quality and diagnostic confidence was done on the pancreaticobiliary tree which was subdivided into 10 segments. They were scored and statistically evaluated separately for visibility and diagnostic certainty by three radiologists with differing levels of experience on a five-point scale of 1 to 5 and -2 to 2, respectively. Student t-test was performed, and the interobserver agreement was also calculated.
Results: Image quality for each segment was significantly better for the 3D-SPACE sequence compared to the 3D-TSE sequence (4.48 ± 0.94 vs. 3.98 ± 1.20; 5-point scale p < 0.01). Diagnostic confidence for the reporting radiologist was also significantly better for 3D-SPACE than for 3D-TSE (1.68 ± 0.56 vs. 1.46 ± 0.70; 3-point scale; p < 0.01). The interobserver agreement was high in both sequences, 0.62 - 0.83 and 0.64 - 0.82, respectively.
Conclusion: The optimized 3D-SPACE sequence allows for better image quality in 1.5 T MRCP examinations and leads to a higher diagnostic confidence for choledocholithiasis compared to the conventional 3D-TSE sequence.
Key Points: • 3D-SPACE allows for better image quality in 1.5 T MRCP.• This leads to a higher diagnostic confidence particularly in the periampullary region.• 3D-SPACE should be considered to substitute conventional 3D-TSE sequences in clinical routine MRCP.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0034-1399271 | DOI Listing |
Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFAm J Rhinol Allergy
January 2025
Department of Otolaryngology - Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA.
Background: The Sino-nasal Outcome Test (SNOT-22) is a 22-question survey that is utilized to evaluate health-related quality of life of patients with chronic rhinosinusitis (CRS). The Patient Global Impression Symptom Severity (PGISS) is a similar yet versatile instrument that combines features of both a Likert scale and a visual analog to assess symptom severity in CRS patients. While previous studies have evaluated the validity of SNOT-22 as an instrument to measure CRS patients' symptom severity, no studies have evaluated PGISS scale's ability to evaluate and guide treatment plans for CRS patients.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National University, Muscat, Muscat, Oman.
Background: This study explores Alzheimer's prediction through brain MRI images, utilizing Convolutional Neural Networks (CNNs) and Lime interpretability. Based on an extensive ADNI MRI dataset, we demonstrate promising results in predicting Alzheimer's disease. Local Interpretable Model Agnostic Explanations (LIME) shed light on decision-making processes, enhancing transparency.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Prevent Alzheimer's Disease 2020, Inc., Rockville, MD, USA.
Background: Disparities in the quality and timeliness of care for Alzheimer's disease (AD) are well documented. This study assessed the impact of demographic characteristics on the diagnosis and management of early AD patients in community-based settings.
Method: This cross-sectional study abstracted medical chart data for patients aged 50-89 years who had newly diagnosed early AD (mild cognitive impairment [MCI] or mild AD) within the past 2 years and a clinic visit within the past 12 months.
J Magn Reson Imaging
January 2025
Department of Radiology, Endeavor Health, Evanston, Illinois, USA.
Background: Luminal and hemodynamic evaluations of the cervical arteries inform the diagnosis and management of patients with cervical arterial disease.
Purpose: To demonstrate a 3D nonenhanced quantitative quiescent interval slice-selective (qQISS) magnetic resonance angiographic (MRA) strategy that provides simultaneous hemodynamic and luminal evaluation of the cervical arteries.
Study Type: Prospective.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!